Skip to main content

Advertisement

SpringerLink
Log in

Tyrosine Kinases: Targets for Epigenetic Influences and a New Direction in the Treatment of Multiple Sclerosis

  • Published:
Neuroscience and Behavioral Physiology Aims and scope Submit manuscript

Studies have shown that tyrosine kinases (TK) may play an important role in the pathogenesis of multiple sclerosis (MS) operating through a microRNA regulatory network. MicroRNA network-based analysis revealed 17 receptor pathways activated by TK and regulated by miRNAs encoded at the DLK1-DIO3 locus on chromosome 14. TK are actively involved in the epigenetic regulation of the pathological process in MS involving the microRNA network, and have attracted attention as targets for the development of new directions in the treatment of MS. Bruton’s TK inhibitors (BTKI) have attracted the most attention, as they have demonstrated their ability to suppress the activity of autoimmune inflammatory lesions in a model of MS, i.e., experimental autoimmune encephalomyelitis (EAE). This is due to the influence of BTK on the activity of B cells, which play a critical role in the development of the pathological process. This review discusses the types of BTKI, the characteristics of their actions in EAE, and results from the first trials in MS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. E. I. Gusev and A. N. Boyko, Multiple Sclerosis. Scientific and Applies Guidelines, ROOI Human Health (2020).

  2. A. Ascherio and K. L. Munger, “Environmental risk factors for multiple sclerosis. Part I & II,” Ann. Neurol., 61, 288–299 and 504–513 (2007), https://doi.org/10.1002/ana.21117 and https://doi.org/10.1002/ana.21141.

  3. N. A. Patsopoulos, S. E. Baranzini, A. Santaniello, et al., “Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility,” Science, 80, 365 (2019), https://doi.org/10.1126/science.aav7188.

    Article  CAS  Google Scholar 

  4. H. A. Lawson, J. M. Cheverud, and J. B. Wolf, “Genomic imprinting and parent-of-origin effects on complex traits,” Nat. Rev. Genet., 14, 609–617 (2013), https://doi.org/10.1038/nrg3543.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. A. N. Baulina, O. I. Kulakova, I. N. Kiselev, et al., “Immune-related miRNA expression patterns in peripheral blood mononuclear cells differ in multiple sclerosis relapse and remission,” J. Neuroimmunol., 317, 67–76 (2018), https://doi.org/10.1016/j.jneuroim.2018.01.005.

    Article  CAS  PubMed  Google Scholar 

  6. A. N. Baulina, G. A. Osmak, I. N. Kiselev, et al., “MiRNAs from DLK1-DIO3 Imprinted Locus at 14q32 are Associated with multiple sclerosis: Gender-specific expression and regulation of receptor tyrosine kinases signaling,” Cells, 8, No. 2, 133–140 (2019), https://doi.org/10.3390/cells8020133.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. J. L. Huynh and P. Casaccia, “Epigenetic mechanisms in multiple sclerosis: implications for pathogenesis and treatment,” Lancet Neurol., 12, No. 2, 195–206 (2013), https://doi.org/10.1016/S1474-4422(12)70309-5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. G. Comi, A. Bar-Or, H. Lassmann, et al., “Role of B cells in multiple sclerosis and related disorders,” Ann. Neurol., 89, 13–23 (2021), https://doi.org/10.1002/ana.25927.

    Article  PubMed  Google Scholar 

  9. M. V. Melnikov, V. S. Rogovskii, et al., “Mechanisms of involvement of B lymphocytes in the pathogenesis of multiple sclerosis,” Med. Ekstrem. Situats., 2, 34–39 (2021).

    Google Scholar 

  10. S. Torke and M. S. Weber, “Inhibition of Bruton’s tyrosine kinase as a novel therapeutic approach in multiple sclerosis,” Expert Opin. Investig. Drugs, 29, No. 10, 1143–1150 (2020), https://doi.org/10.1080/13543784.2020.1807934.

    Article  CAS  PubMed  Google Scholar 

  11. Z. Pan, H. Scheerens, S. J. Li, et al., “Discovery of selective irreversible inhibitors for Bruton’s tyrosine kinase,” ChemMedChem, 2, 58–61 (2007), https://doi.org/10.1002/cmdc.200600221.

    Article  CAS  PubMed  Google Scholar 

  12. J. Zheng, J. Wu, X. Ding, et al., “Small molecule approaches to treat autoimmune and inflammatory diseases (Part I, kinase inhibitors,” Bioorg. Med. Chem. Lett., 38, 127862 (2021), https://doi.org/10.1016/j.bmcl.2021.127862.

  13. R. W. Hendriks, S. Yuvaraj, and L. P. Kil, “Targeting Bruton’s tyrosine kinase in B cell malignancies,” Nat. Rev. Cancer, 14, 219–232 (2014), https://doi.org/10.1038/nrc3702.

    Article  CAS  PubMed  Google Scholar 

  14. C. Liang, D. Tian, X. Ren, et al., “The development of Bruton’s tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review,” Eur. J. Med. Chem., 151, 315–326 (2018), https://doi.org/10.1016/j.ejmech.2018.03.062.

    Article  CAS  PubMed  Google Scholar 

  15. H. Y. Estupiñán, A. Berglöf, R. Zain, and C. E. Smith, “Comparative analysis of BTK inhibitors and mechanisms underlying adverse effects,” Front. Cell. Dev. Biol., 9, 630942 (2021), https://doi.org/10.3389/fcell.2021.630942.

  16. Q. Liu, Y. Sabnis, Z. Zhao, et al., “Developing irreversible inhibitors of the protein kinase cysteinome,” Chem. Biol., 20, 146–159 (2013), https://doi.org/10.1016/j.chembiol.2012.12.006.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. D. Gu, H. Tang, J. Wu, et al., “Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies,” J. Hematol. Oncol., 14, 40 (2021), https://doi.org/10.1186/s13045-021-01049-7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. O. Crespo, S. C. Kang, R. Daneman, et al., “Tyrosine kinase inhibitors ameliorate autoimmune encephalomyelitis in a mouse model of multiple sclerosis,” J. Clin. Immunol., 31, 1010–1020 (2011), https://doi.org/10.1007/s10875-011-9579-6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. C. Menzfeld, M. John, D. van Rossum, et al., “Tyrphostin AG126 exerts neuroprotection in CNS inflammation by a dual mechanism: AG126 in autoimmunity and inflammation,” Glia, 63, 1083–1099 (2015), https://doi.org/10.1002/glia.22803.

    Article  PubMed  Google Scholar 

  20. S. Torke, R. Pretzsch, D. Häusler, et al., “Inhibition of Bruton’s tyrosine kinase interferes with pathogenic b-cell development in inflammatory CNS demyelinating disease,” Acta Neuropathol., 140, 535–548 (2020), https://doi.org/10.1007/s00401-020-02204-z.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. S. Syed, N. Yonkers, C. LaGanke, et al., “Efficacy and safety of tolebrutinib in patients with highly active relapsing MS: Subgroup analysis of the phase 2b study,” Neurology, 96, S15, 2260 (2021).

  22. A.García-Merino, “Bruton’s tyrosine kinase inhibitors: A new generation of promising agents for multiple sclerosis therapy,” Cells, 10, No. 10, 2560 (2021), https://doi.org/10.3390/cells10102560.

  23. J. J. Crawford, A. R. Johnson, D. L. Misner, et al., “Discovery of GDC-0853: A potent, selective, and noncovalent Bruton’s tyrosine kinase inhibitor in early clinical development,” J. Med. Chem., 61, 2227–2245 (2018), https://doi.org/10.1021/acs.jmedchem.7b01712.

    Article  CAS  PubMed  Google Scholar 

  24. X. Montalban, D. L. Arnold, M. S. Weber, et al., “Placebo-controlled trial of an oral BTK inhibitor in multiple sclerosis,” N. Engl. J. Med., 380, 2406–2417 (2019), https://doi.org/10.1056/NEJMoa1901981.

    Article  CAS  PubMed  Google Scholar 

  25. S. Dhillon, “Orelabrutinib: First approval,” Drugs, 81, 503–507 (2021), https://doi.org/10.1007/s40265-021-01482-5.

    Article  CAS  PubMed  Google Scholar 

  26. L. J. Crofford, L. E. Nyhoff, J. H. Sheehan, et al., “The role of Bruton’s tyrosine kinase in autoimmunity and implications for therapy,” Expert Rev. Clin. Immunol., 12, 763–773 (2016), https://doi.org/10.1586/1744666X.2016.1152888.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. A. Steinmaurer, I. Wimmer, T. Berger, et al., “Bruton’s tyrosine kinase inhibition in the treatment of preclinical models and multiple sclerosis,” Curr. Pharm. Des., 28, No. 6, 437–444 (2022), https://doi.org/10.2174/1381612827666210701152934.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pirogov Russian National Research Medical University, Russian Ministry of Health, Moscow, Russia

    A. N. Boyko

  2. Federal Center for the Brain Research and Neurotechnologies, Federal Medical Biological Agency of Russia, Moscow, Russia

    A. N. Boyko

Authors
  1. A. N. Boyko
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. N. Boyko.

Additional information

Translated from Zhurnal Nevrologii i Psikhiatrii imeni S. S. Korsakova, Vol. 122, No. 7, Iss. 2, pp. 27–30, July, 2022.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Boyko, A.N. Tyrosine Kinases: Targets for Epigenetic Influences and a New Direction in the Treatment of Multiple Sclerosis. Neurosci Behav Physi 53, 333–336 (2023). https://doi.org/10.1007/s11055-023-01430-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11055-023-01430-8

Keywords

Search

Navigation